125 related articles for article (PubMed ID: 12529867)
1. A parametric model for long-term follow-up data from phase III breast cancer clinical trials.
Jeong JH; Jung SH; Wieand S
Stat Med; 2003 Feb; 22(3):339-52. PubMed ID: 12529867
[TBL] [Abstract][Full Text] [Related]
2. Phase III trials of toremifene vs tamoxifen.
Gams R
Oncology (Williston Park); 1997 May; 11(5 Suppl 4):23-8. PubMed ID: 9165503
[TBL] [Abstract][Full Text] [Related]
3. Patterns of treatment effects in subsets of patients in clinical trials.
Bonetti M; Gelber RD
Biostatistics; 2004 Jul; 5(3):465-81. PubMed ID: 15208206
[TBL] [Abstract][Full Text] [Related]
4. Survival after adjuvant oophorectomy and tamoxifen in operable breast cancer in premenopausal women.
Love RR; Van Dinh N; Quy TT; Linh ND; Tung ND; Shen TZ; Hade EM; Young GS; Jarjoura D
J Clin Oncol; 2008 Jan; 26(2):253-7. PubMed ID: 18086800
[TBL] [Abstract][Full Text] [Related]
5. Is there a role for adjuvant tamoxifen in progesterone receptor-positive breast cancer? An in silico clinical trial.
Hilsenbeck SG; Osborne CK
Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1049s-1055s. PubMed ID: 16467123
[TBL] [Abstract][Full Text] [Related]
6. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
[TBL] [Abstract][Full Text] [Related]
7. The role of aromatase inhibitors as adjuvant therapy for early breast cancer in postmenopausal women.
Mouridsen HT; Robert NJ
Eur J Cancer; 2005 Aug; 41(12):1678-89. PubMed ID: 16098456
[TBL] [Abstract][Full Text] [Related]
8. Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.
Berry J
Clin Ther; 2005 Nov; 27(11):1671-84. PubMed ID: 16368441
[TBL] [Abstract][Full Text] [Related]
9. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999.
Mariotto AB; Feuer EJ; Harlan LC; Abrams J
J Natl Cancer Inst Monogr; 2006; (36):7-15. PubMed ID: 17032888
[TBL] [Abstract][Full Text] [Related]
10. Clinical decision making in breast cancer: TAM and aromatase inhibitors for older patients -- a jungle?
Biganzoli L; Licitra S; Claudino W; Pestrin M; Leo AD
Eur J Cancer; 2007 Oct; 43(15):2270-8. PubMed ID: 17698345
[TBL] [Abstract][Full Text] [Related]
11. Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer: a randomised phase III trial of the European Organisation for Research and Treatment of Cancer Breast Group.
Morales L; Canney P; Dyczka J; Rutgers E; Coleman R; Cufer T; Welnicka-Jaskiewicz M; Nortier J; Bogaerts J; Therasse P; Paridaens R; ;
Eur J Cancer; 2007 Jan; 43(2):331-40. PubMed ID: 17134892
[TBL] [Abstract][Full Text] [Related]
12. Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer.
Hillner BE
Cancer; 2004 Sep; 101(6):1311-22. PubMed ID: 15368322
[TBL] [Abstract][Full Text] [Related]
13. Letrozole in the extended adjuvant treatment of postmenopausal women with history of early-stage breast cancer who have completed 5 years of adjuvant tamoxifen.
Mann BS; Johnson JR; Kelly R; Sridhara R; Williams G; Pazdur R
Clin Cancer Res; 2005 Aug; 11(16):5671-7. PubMed ID: 16115902
[TBL] [Abstract][Full Text] [Related]
14. Endogenous sex hormones, breast cancer risk, and tamoxifen response: an ancillary study in the NSABP Breast Cancer Prevention Trial (P-1).
Beattie MS; Costantino JP; Cummings SR; Wickerham DL; Vogel VG; Dowsett M; Folkerd EJ; Willett WC; Wolmark N; Hankinson SE
J Natl Cancer Inst; 2006 Jan; 98(2):110-5. PubMed ID: 16418513
[TBL] [Abstract][Full Text] [Related]
15. Joint modeling of progression-free survival and death in advanced cancer clinical trials.
Dejardin D; Lesaffre E; Verbeke G
Stat Med; 2010 Jul; 29(16):1724-34. PubMed ID: 20572123
[TBL] [Abstract][Full Text] [Related]
16. A method for sequential analysis of survival data with nonproportional hazards.
Sooriyarachchi MR; Whitehead J
Biometrics; 1998 Sep; 54(3):1072-84. PubMed ID: 9750253
[TBL] [Abstract][Full Text] [Related]
17. The Breast International Group 1-98 trial: big results for women with hormone-sensitive early breast cancer.
Monnier AM
Expert Rev Anticancer Ther; 2007 May; 7(5):627-34. PubMed ID: 17492927
[TBL] [Abstract][Full Text] [Related]
18. Adherence to endocrine therapy for breast cancer.
Chlebowski RT; Geller ML
Oncology; 2006; 71(1-2):1-9. PubMed ID: 17344666
[TBL] [Abstract][Full Text] [Related]
19. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
Coates AS; Keshaviah A; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Colleoni M; Láng I; Del Mastro L; Smith I; Chirgwin J; Nogaret JM; Pienkowski T; Wardley A; Jakobsen EH; Price KN; Goldhirsch A
J Clin Oncol; 2007 Feb; 25(5):486-92. PubMed ID: 17200148
[TBL] [Abstract][Full Text] [Related]
20. Prognosis of uterine corpus cancer after tamoxifen treatment for breast cancer.
Hoogendoorn WE; Hollema H; van Boven HH; Bergman E; de Leeuw-Mantel G; Platteel I; Fles R; Nederlof PM; Mourits MJ; van Leeuwen FE;
Breast Cancer Res Treat; 2008 Nov; 112(1):99-108. PubMed ID: 18064567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]